1. Industry
Send to a Friend via Email

Your suggestion is on its way!

An email with a link to:

http://pharma.about.com/od/Generics/a/Generic-Drug-Pipeline.htm

was emailed to:

Thanks for sharing About.com with others!

You can opt-out at any time. Please refer to our privacy policy for contact information.

Generic Drug Pipeline

By

The growth of the generic drug market is four times higher than the pharmaceutical market overall, and generics are poised to take an even bigger bite of the prescription drug market as more branded drugs go off patent.

While it is possible to project generic launches based on U.S. Food and Drug Administration (FDA) approvals (published in the "Orange Book") and the date a branded drug is to expire, there are many factors that put generic launches at risk, according to Diana Papshev, Pharm D, a partner with DrugManagementForum.com. Papshev outlined the projected generic launches at the April 2011 meeting of the Academy of Managed Care Pharmacy.

Generic launches projected for 2011:

Caduit, cardiovascular

Lipitor, cardiovascular

Tricor, cardiovascular

Zyprexa, antipsychotic

Zyprexa Zyris, antipsychotic

Symbyax, antispychotic

Generic launches anticipated for 2012:

Actos, diabetes

Actoplus Met, diabetes

Avandamet, diabetes

Avandaryl, diabetes

Tricor, cardiovascular

Diovan HCT, diabetes

Focatin XR, stimulant

Invega, antipsychotic

Lescol, cardiovascular

Lescol XL, cardiovascular

Lexapro, antidepressant

Plavix, anti-platelet

Provigil, stimulant

Seroquel, antipsychotic

©2014 About.com. All rights reserved.